IMU - Imuniti - Trial Results and Withdrawal of Cautionary Announcement

IMU - Imuniti - Trial Results and Withdrawal of Cautionary Announcement         
IMUNITI HOLDINGS LIMITED                                                        
(Incorporated in the Republic of South Africa)                                  
(Registration number 2004/002282/06)                                            
(JSE Code: IMU & ISIN: ZAE000089199)                                            
("Imuniti" or "the Company")                                                    
TRIAL RESULTS AND WITHDRAWAL OF CAUTIONARY ANNOUNCEMENT                         
TRIAL RESULTS ON IMUNITI PACK                                                   
Shareholders are referred to the cautionary announcement published on 14 March  
2011.                                                                           
Imuniti manufactures the Imuniti Nutritional Supplement Combo (INSCP) Pack for  
Edge to Edge Global Investments Limited (E2E), the owners of the intellectual   
property related to the Imuniti Pack. E2E have advised in a press release the   
following:                                                                      
A clinical trial was conducted on HIV positive patients. The clinical trial was 
conducted by Prof Luc Montagnier on the INCSPin conjunction with ARV therapy,   
conducted at the Centre Integre de Recherches Biocliniques d`Abidjan            
(C.I.R.B.A.), Cote d`Ivoire (under the auspices of UNESCO).                     
What was clearly observed on this first preliminary trial was the following:    
1.   Using the new biomarker developed by Professor Montagnier to measure the   
    remaining viral DNA in the body after ARV treatment and also using the      
    current standard of measurement namely PCR measurement, the following trend 
    was observed:                                                               
a.   The control arm of ARV alone showed no change in any of the markers    
         requested as per trial protocol.                                       
    b.   The ARV plus INSCP arm showed a substantial reduction in the viral DNA 
         in 71% of the patients. Furthermore, PCR showed that 28% of the        
patients had viral DNA disappear after three months of INSCP           
         treatment. This is the first time that this viral DNA has ever been    
         impacted by a natural combination product.                             
2.   The preliminary results justify further clinical trials with a larger      
number of patients.  It is also envisaged to use INSCP in HIV positive      
    naive patients not yet treated by ARVs.                                     
WITHDRAWAL OF CAUTIONARY ANNOUNCEMENT                                           
Shareholders are referred to the cautionary announcement issued on 14 March     
2011, and are advised that they no longer need to exercise caution in dealing   
with the shares of Imuniti in relation to the prior cautionary announcement.    
DURBAN                                                                          
23 March 2011                                                                   
Designated Advisor                                                              
Arcay Moela (Proprietary) Limited                                               
Date: 23/03/2011 10:35:01 Supplied by www.sharenet.co.za                     
Produced by the JSE SENS Department.                  
The SENS service is an information dissemination service administered by the    
JSE Limited (`JSE`). The JSE does not, whether expressly, tacitly or            
implicitly, represent, warrant or in any way guarantee the truth, accuracy or   
completeness of the information published on SENS. The JSE, their officers,     
employees and agents accept no liability for (or in respect of) any direct,     
indirect, incidental or consequential loss or damage of any kind or nature,     
howsoever arising, from the use of SENS or the use of, or reliance on,          
information disseminated through SENS.